Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>HBX 19818

HBX 19818

Katalog-Nr.GC36211

HBX 19818 ist ein spezifischer Inhibitor der Ubiquitin-spezifischen Protease 7 (USP7) mit einem IC50 von 28,1 μM.

Products are for research use only. Not for human use. We do not sell to patients.

HBX 19818 Chemische Struktur

Cas No.: 1426944-49-1

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
201,00 $
Auf Lager
2mg
108,00 $
Auf Lager
5mg
216,00 $
Auf Lager
10mg
356,00 $
Auf Lager
50mg
990,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

HBX 19818 is a specific inhibitor of ubiquitin-specific protease 7 (USP7), with an IC50 of 28.1 μM. IC50: 28.1 μM (USP7)[1]

HBX 19818 is an inhibitor of USP7, with an IC50 of 28.1 μM. HBX 19818 shows no effects on USP8, USP5, USP10, CYLD, UCH-L1, UCH-L3 or on SENP1, a SUMO protease, with IC50s of > 200 μM. HBX 19818 selectively inhibits USP7 with IC50 of ∼6 μM in in human cancer cells. In addition, HBX 19818 (1.5, 4, 12, 36, or 100 μM) inhibits USP7 deubiquitination of polyubiquitinated p53. HBX 19818 (30 μM) also causes significantly higher levels of Mdm2 polyubiquitinated forms in USP7-overproducing HEK293 cells than those in DMSO-treated control cells. HBX 19818 inhibits HCT116 proliferation in a dose-dependent manner, with an IC50 of ∼2 μM[1].

[1]. Reverdy C, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 2012 Apr 20;19(4):467-77.

Bewertungen

Review for HBX 19818

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for HBX 19818

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.